Big verdict doesn't assure more wins for plaintiffs in talc-cancer cases

NEW YORK, Feb 25 (Reuters) - The $72 million verdict this week against Johnson & Johnson in a U.S. case alleging links between talc-based powder and ovarian cancer has prompted global headlines, social media buzz and calls to lawyers from would-be plaintiffs.


Read more